{"slideshow_credits": null, "snippet": "The Food and Drug Administration finally required that mefloquine hydrochloride, brand name Lariam, carry a \u201cblack box\u201d for side effects. But it\u2019s too little, too late.", "abstract": "Op-Ed article by author David Stuart MacLean describes suffering from severe adverse psychiatric side effects from taking anti-malarial drug mefloquine hydrochloride; notes that the Food and Drug Administration has finally acknowledged that neurological and psychiatric side effects of the drug are serious enough to warrant a warning label; laments that the FDA decision has come too late, as the side effects could be permanent.", "section_name": "Opinion", "print_page": "23", "document_type": "article", "byline": {"person": [{"lastname": "MacLEAN", "rank": 1, "firstname": "David", "role": "reported", "organization": "", "middlename": "Stuart"}], "original": "By DAVID STUART MacLEAN", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/08/08/opinion/crazy-pills.html", "lead_paragraph": "The Food and Drug Administration finally required that mefloquine hydrochloride, brand name Lariam, carry a \u201cblack box\u201d for side effects. But it\u2019s too little, too late.", "headline": {"main": "Crazy Pills", "print_headline": "Crazy Pills", "content_kicker": "Op-Ed Contributor", "kicker": "Op-Ed Contributor"}, "_id": "5202ee4238f0d8740ac8a4b7", "word_count": "834", "multimedia": [{"height": 126, "url": "images/2013/08/08/opinion/0808OPEDsampson/0808OPEDsampson-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/08/08/opinion/0808OPEDsampson/0808OPEDsampson-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 835, "url": "images/2013/08/08/opinion/0808OPEDsampson/0808OPEDsampson-articleLarge.jpg", "legacy": {"xlarge": "images/2013/08/08/opinion/0808OPEDsampson/0808OPEDsampson-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "835"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/08/08/opinion/0808OPEDsampson/0808OPEDsampson-thumbStandard.jpg", "legacy": {"thumbnail": "images/2013/08/08/opinion/0808OPEDsampson/0808OPEDsampson-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-08-08T00:00:00Z", "source": "The New York Times", "news_desk": "OpEd", "keywords": [{"value": "Malaria", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "2"}, {"value": "Labeling and Labels", "name": "subject", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "Op-Ed"}